2024-11-21 00:31:40
Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
Health/ 2023-07-22
Hinova Announces First Patient Dosed in ...

MELBOURNE,Australia,Jan. 20,2022--Hinova Pharmaceuticals Inc.,a clinical-stage biopharmaceutical company focused on developing novel therape...

Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas
Corporate/ 2023-07-24
Volition presents study data at ASCO GI ...

AUSTIN,Texas,Jan. 20,2022--VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"),a multi-national epigenetics company,has announce...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release